837 results on '"Donohue, James"'
Search Results
2. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
3. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD
4. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
5. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
6. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease
7. Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
8. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials
9. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease
10. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease
11. Improving the Management of COPD in Women
12. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year
13. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
14. Genre-based literacy pedagogy : the nature and value of genre knowledge in teaching and learning writing on a university first year media studies course
15. Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
16. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD
17. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials
18. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
19. Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease
20. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective
21. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B
22. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
23. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D
24. Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations
25. One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD
26. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation
27. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease
28. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
29. Current Perspectives of Pharmacotherapies for COPD.
30. Investigating the Relationship between the Use of English for Academic Purposes and Academic Attainment
31. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis
32. Academic Literacies and Systemic Functional Linguistics: How Do They Relate?
33. Using Systemic Functional Linguistics in Academic Writing Development: An Example from Film Studies
34. Population-Based Burden of COPD-Related Visits in the ED: Return ED Visits, Hospital Admissions, and Comorbidity Risks
35. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates
36. How to Support a One-Handed Economist: The Role of Modalisation in Economic Forecasting
37. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
38. The Jim Pitts Site: A Stratified Paleoindian Site in the Black Hills of South Dakota
39. Bronchodilator Reversibility in COPD
40. The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development
41. Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire
42. Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD
43. Do Symptoms Predict COPD in Smokers?
44. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ)
45. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
46. Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study
47. CXCR2 Antagonist MK-7123: A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease
48. The ATS Foundation. 10 Years Old and Powered to Grow
49. Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers
50. Techniques in Evaluation of Rapid Antisyphilitic Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.